Providers sounded the alarm Thursday, saying the <i>Dobbs</i> decision has stopped health professionals from using their best judgment and limited access to medicines.
The FDA’s advisory committee on neurological drugs voted in favor of recommending the agency approve a novel amyotrophic lateral sclerosis drug candidate.